Winston-Salem, North Carolina Oct 29, 2007
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics (TM), today announced that J. Donald deBethizy, Ph.D., President and Chief Executive Officer, is scheduled to present at two upcoming investor conferences:
Each presentation will be webcast and accessible from the Investor Relations page of the Company’s website at www.targacept.com. Each webcast will also be available for replay on the Company’s website for at least two weeks following the corresponding event. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled start time.
About Targacept
Targacept is a clinical-stage biopharmaceutical company that discovers and develops NNR Therapeutics (TM), a new class of drugs for the treatment of central nervous system diseases and disorders. Its product candidates selectively modulate neuronal nicotinic receptors that serve as key regulators of the nervous system to promote therapeutic effects and limit adverse side effects. Targacept has product candidates in development for Alzheimer's disease and cognitive deficits in schizophrenia, pain, and depression and anxiety disorders, as well as multiple preclinical programs. Targacept also has strategic alliances with AstraZeneca and GlaxoSmithKline. Additional information about Targacept is available at www.targacept.com.
Contacts:
Alan Musso, VP and CFO
Targacept, Inc.
Tel: (336) 480-2186
Email: alan.musso@targacept.com
Michelle Linn
Linnden Communications
Tel: (508) 419-1555
Email: linnmich@comcast.net